nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,days_since_update
NCT04558125,NA,2020-09-19,2021-09-21,NA,2021-10-20,2020-09-21,2020-09-22,Actual,2021-10-20,2021-10-26,Actual,NA,NA,NA,2021-10-20,2021-10-26,Actual,"September 8, 2020",Actual,2020-09-08,October 2021,2021-10-31,"August 8, 2021",Actual,2021-08-08,"July 10, 2021",Actual,2021-07-10,NA,Interventional,NA,"The study was terminated early and never unblinded. With only 2 subjects, statistical significance could never be demonstrated. Therefore, Arm/Group randomization information is not available.",Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism,"Low-Dose Tenecteplase in Covid-19 Patients With Acute Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial",Terminated,NA,Phase 4,2,Actual,Cedars-Sinai Medical Center,NA,2,NA,Identification of eligible patients was slower than anticipated.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:58:14Z,2021-12-04T22:58:14Z,75
NCT04381988,NA,2020-05-08,2021-10-25,NA,2021-10-25,2020-05-08,2020-05-11,Actual,2021-10-25,2021-10-27,Actual,NA,NA,NA,2021-10-25,2021-10-27,Actual,"May 7, 2020",Actual,2020-05-07,April 2021,2021-04-30,"April 21, 2021",Actual,2021-04-21,"April 21, 2021",Actual,2021-04-21,NA,Interventional,NA,The study was terminated before more participants were accrued.,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID),Terminated,NA,Phase 2,4,Actual,Memorial Sloan Kettering Cancer Center,NA,2,NA,The study was terminated based results of other studies and use of the new vaccine.,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2021-12-04T22:58:18Z,2021-12-04T22:58:18Z,70
NCT04524507,NA,2020-08-21,2021-11-15,NA,2021-12-01,2020-08-21,2020-08-24,Actual,2021-11-15,2021-11-23,Actual,NA,NA,NA,2021-12-01,2021-12-03,Estimate,"August 27, 2020",Actual,2020-08-27,June 2021,2021-06-30,"June 4, 2021",Actual,2021-06-04,"January 4, 2021",Actual,2021-01-04,NA,Interventional,UNC CCP RCT,NA,Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients,"IGHID 12021 - A Randomized, Phase II Study Comparing the Efficacy and Safety of Standard Versus High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Plasma in Hospitalized Patients With COVID-19",Completed,NA,Phase 2,56,Actual,"University of North Carolina, Chapel Hill",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,12-24 months after publication,"Investigators/researchers who propose to use study data will need to have IRB, IEC, or REB approval and an executed data use/sharing agreement with UNC.",NA,Yes,"De-identified individual data that supports the results will be shared beginning 12 to 24 months following publication provided the investigator/researcher who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2021-12-06T10:40:55Z,2021-12-06T10:40:55Z,33
NCT04425538,NA,2020-06-08,2021-08-23,NA,2021-12-01,2020-06-08,2020-06-11,Actual,2021-12-01,2021-12-03,Estimate,NA,NA,NA,2021-12-01,2021-12-03,Estimate,"June 1, 2020",Actual,2020-06-01,December 2021,2021-12-31,"January 22, 2021",Actual,2021-01-22,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,NA,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,Completed,NA,Phase 2,17,Actual,Tufts Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T10:42:16Z,2021-12-06T10:42:16Z,33
NCT04382924,NA,2020-05-08,2021-11-22,NA,2021-12-01,2020-05-08,2020-05-11,Actual,2021-12-01,2021-12-03,Estimate,NA,NA,NA,2021-12-01,2021-12-03,Estimate,"August 5, 2020",Actual,2020-08-05,December 2021,2021-12-31,"January 26, 2021",Actual,2021-01-26,"December 24, 2020",Actual,2020-12-24,NA,Interventional,NA,NA,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,Completed,NA,Phase 2/Phase 3,168,Actual,Algernon Pharmaceuticals,NA,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-06T10:42:42Z,2021-12-06T10:42:42Z,33
NCT04344535,NA,2020-04-10,2021-09-20,NA,2021-12-02,2020-04-13,2020-04-14,Actual,2021-12-02,2021-12-06,Estimate,NA,NA,NA,2021-12-02,2021-12-06,Estimate,"April 8, 2020",Actual,2020-04-08,December 2021,2021-12-31,"February 1, 2021",Actual,2021-02-01,"January 1, 2021",Actual,2021-01-01,NA,Interventional,NA,NA,Convalescent Plasma vs. Standard Plasma for COVID-19,Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection: A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection,Terminated,NA,Phase 1/Phase 2,82,Actual,Stony Brook University,NA,2,NA,Insufficient eligible and consenting patients,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T20:13:53Z,2021-12-06T20:13:53Z,32
NCT04355728,NA,2020-04-13,2021-10-15,NA,2021-12-01,2020-04-17,2020-04-21,Actual,2021-12-01,2021-12-06,Estimate,NA,NA,NA,2021-12-01,2021-12-06,Estimate,"April 25, 2020",Actual,2020-04-25,December 2021,2021-12-31,"October 31, 2020",Actual,2020-10-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,NA,Use of UC-MSCs for COVID-19 Patients,Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS),Completed,NA,Phase 1/Phase 2,24,Actual,University of Miami,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T20:13:48Z,2021-12-06T20:13:48Z,33
NCT04446429,NA,2020-06-22,2021-01-22,NA,2021-12-08,2020-06-23,2020-06-24,Actual,2021-01-29,2021-02-03,Actual,NA,NA,NA,2021-12-08,2021-12-10,Estimate,"October 21, 2020",Actual,2020-10-21,December 2021,2021-12-31,"January 21, 2021",Actual,2021-01-21,"December 24, 2020",Actual,2020-12-24,NA,Interventional,NA,NA,Anti-Androgen Treatment for COVID-19,Anti-Androgen Treatment for COVID-19,Completed,NA,Not Applicable,268,Actual,"Applied Biology, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-13T10:24:19Z,2021-12-13T10:24:19Z,26
NCT04331366,NA,2020-03-31,2021-02-05,NA,2021-02-16,2020-03-31,2020-04-02,Actual,2021-02-05,2021-02-10,Actual,NA,NA,NA,2021-02-16,2021-02-18,Actual,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,GO2 PEEP,NA,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,NA,Not Applicable,2,Actual,Emory University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-13T22:54:58Z,2021-12-13T22:54:58Z,321
NCT04372017,NA,2020-04-25,2021-12-06,NA,2021-12-08,2020-04-30,2020-05-01,Actual,2021-12-08,2021-12-10,Estimate,NA,NA,NA,2021-12-08,2021-12-10,Estimate,"May 14, 2020",Actual,2020-05-14,December 2021,2021-12-31,"June 4, 2021",Actual,2021-06-04,"June 4, 2021",Actual,2021-06-04,NA,Interventional,NA,No subjects or data analyzed. Study was closed to enrollment before analysis.,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,"Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection",Terminated,NA,Phase 3,1,Actual,Sanford Health,NA,4,NA,Unlikelihood of benefit based on other studies.,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-13T10:24:58Z,2021-12-13T10:24:58Z,26
NCT04876274,NA,2021-05-05,2021-10-05,NA,2021-11-03,2021-05-05,2021-05-06,Actual,2021-11-03,2021-12-13,Estimate,NA,NA,NA,2021-11-03,2021-12-13,Estimate,"July 14, 2020",Actual,2020-07-14,November 2021,2021-11-30,"December 29, 2020",Actual,2020-12-29,"December 29, 2020",Actual,2020-12-29,NA,Interventional,NA,NA,Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic,Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic: a Randomized Controlled Trial in Taiwan,Completed,NA,Not Applicable,181,Actual,Taipei Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:37:25Z,2021-12-14T09:37:25Z,61
NCT04524598,NA,2020-08-20,2021-09-30,NA,2021-12-09,2020-08-20,2020-08-24,Actual,2021-12-09,2021-12-13,Estimate,NA,NA,NA,2021-12-09,2021-12-13,Estimate,"July 20, 2020",Actual,2020-07-20,December 2021,2021-12-31,"January 16, 2022",Anticipated,2022-01-16,"September 3, 2021",Actual,2021-09-03,NA,Interventional,NA,NA,A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,Limbix Spark: A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,"Active, not recruiting",NA,Not Applicable,227,Actual,"Limbix Health, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:40:04Z,2021-12-14T09:40:04Z,25
NCT04456153,NA,2020-06-30,2021-11-10,NA,2021-12-12,2020-06-30,2020-07-02,Actual,2021-12-12,2021-12-14,Estimate,NA,NA,NA,2021-12-12,2021-12-14,Estimate,"July 22, 2020",Actual,2020-07-22,December 2021,2021-12-31,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,NA,Atovaquone for Treatment of COVID-19,Atovaquone for Treatment of COVID-19,Completed,NA,Phase 2,60,Actual,University of Texas Southwestern Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,There is no specified plan made.,2021-12-15T09:18:20Z,2021-12-15T09:18:20Z,22
NCT04351243,NA,2020-04-15,2021-11-26,NA,2021-12-10,2020-04-15,2020-04-17,Actual,2021-12-06,2021-12-10,Actual,NA,NA,NA,2021-12-10,2021-12-14,Estimate,"April 15, 2020",Actual,2020-04-15,December 2021,2021-12-31,"April 1, 2021",Actual,2021-04-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),"A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)",Completed,NA,Phase 2,227,Actual,Kinevant Sciences GmbH,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-15T09:19:10Z,2021-12-15T09:19:10Z,24
NCT04328961,NA,2020-03-23,2021-10-08,NA,2021-12-14,2020-03-29,2020-04-01,Actual,2021-12-14,2021-12-16,Estimate,NA,NA,NA,2021-12-14,2021-12-16,Estimate,"March 31, 2020",Actual,2020-03-31,December 2021,2021-12-31,"October 8, 2020",Actual,2020-10-08,"September 24, 2020",Actual,2020-09-24,NA,Interventional,NA,The above participants contributed to the Modified Intention-to-Treat Cohort.,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",Completed,NA,Phase 2/Phase 3,943,Actual,University of Washington,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2021-12-17T09:25:19Z,2021-12-17T09:25:19Z,20
NCT04644328,NA,2020-11-13,2021-10-26,NA,2021-12-15,2020-11-20,2020-11-25,Actual,2021-12-15,2021-12-21,Estimate,NA,NA,NA,2021-12-15,2021-12-21,Estimate,"November 12, 2020",Actual,2020-11-12,December 2021,2021-12-31,"February 11, 2021",Actual,2021-02-11,"February 11, 2021",Actual,2021-02-11,NA,Interventional,NA,"The experiment was run during two periods: Thanksgiving (Period 1) and Christmas (Period 2). During Thanksgiving, 820 counties were analyzed (410 high-intensity, 410 low-intensity). Of these counties, 767 were analyzed during Christmas (386 high-intensity, 381 low-intensity). Fewer counties were analyzed at Christmas because we removed counties in rural, conservative areas from the study due to potential negative impacts resulting from polarization in the wake of the 2020 presidential election.",The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign,The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign,Completed,NA,Not Applicable,820,Actual,"National Bureau of Economic Research, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The pre-analysis plan will be posted publicly. The ability to share IPD will be based on discussions with our partner organization.,2021-12-22T09:18:25Z,2021-12-22T09:18:25Z,19
NCT05057923,NA,2021-09-21,2021-12-18,NA,2021-12-22,2021-09-23,2021-09-27,Actual,2021-12-22,2021-12-23,Actual,NA,NA,NA,2021-12-22,2021-12-23,Actual,"July 10, 2021",Actual,2021-07-10,December 2021,2021-12-31,"November 1, 2021",Actual,2021-11-01,"October 20, 2021",Actual,2021-10-20,NA,Interventional,NA,The baseline population does not differ from the participant flow.,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores Expressing and Displaying the Receptor Binding Domain of Spike Protein of SARS-COV2,Completed,NA,Not Applicable,9,Actual,DreamTec Research Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:25:59Z,2021-12-29T08:25:59Z,12
NCT04632706,NA,2020-10-26,2021-12-14,NA,2021-12-22,2020-11-16,2020-11-17,Actual,2021-12-22,2021-12-27,Actual,NA,NA,NA,2021-12-22,2021-12-27,Actual,"September 22, 2020",Actual,2020-09-22,December 2021,2021-12-31,"March 9, 2021",Actual,2021-03-09,"March 9, 2021",Actual,2021-03-09,NA,Interventional,NA,NA,Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19,"A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers",Completed,NA,Phase 1,24,Actual,MedinCell S.A,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:34:54Z,2021-12-29T08:34:54Z,12
NCT04498247,NA,2020-08-03,2021-12-20,NA,2021-12-20,2020-08-03,2020-08-04,Actual,2021-12-20,2021-12-23,Actual,NA,NA,NA,2021-12-20,2021-12-23,Actual,"August 27, 2020",Actual,2020-08-27,December 2021,2021-12-31,"March 5, 2021",Actual,2021-03-05,"March 5, 2021",Actual,2021-03-05,NA,Interventional,NA,NA,"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)","A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants",Terminated,NA,Phase 1/Phase 2,263,Actual,Merck Sharp & Dohme Corp.,NA,10,NA,The study was terminated based on an interim assessment of immunogenicity,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-12-29T08:37:21Z,2021-12-29T08:37:21Z,14
NCT04359797,NA,2020-04-20,2021-12-13,NA,2021-12-22,2020-04-20,2020-04-24,Actual,2021-12-22,2021-12-27,Actual,NA,NA,NA,2021-12-22,2021-12-27,Actual,"April 27, 2020",Actual,2020-04-27,December 2021,2021-12-31,"January 17, 2021",Actual,2021-01-17,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,NA,COVID-19 Patient Positioning Pragmatic Trial,Pragmatic Trial Exploring Impact of Patient Positioning in the Management of Patients Infected With COVID-19: Supine vs. Prone,Completed,NA,Not Applicable,501,Actual,Vanderbilt University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.,Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.,NA,Yes,Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.,2021-12-29T08:39:21Z,2021-12-29T08:39:21Z,12
NCT04569786,NA,2020-09-24,2021-12-22,NA,2021-12-22,2020-09-24,2020-09-30,Actual,2021-12-22,2021-12-29,Actual,NA,NA,NA,2021-12-22,2021-12-29,Actual,"October 29, 2020",Actual,2020-10-29,December 2021,2021-12-31,"February 18, 2021",Actual,2021-02-18,"February 18, 2021",Actual,2021-02-18,NA,Interventional,NA,NA,Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults",Terminated,NA,Phase 1,232,Actual,Merck Sharp & Dohme Corp.,NA,9,NA,The study was terminated based on an interim assessment of immunogenicity.,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-12-30T20:44:05Z,2021-12-30T20:44:05Z,12
NCT04871815,NA,2021-04-27,2021-09-27,NA,2021-10-05,2021-04-30,2021-05-04,Actual,2021-10-05,2021-10-07,Actual,NA,NA,NA,2021-10-05,2021-10-07,Actual,"April 27, 2021",Actual,2021-04-27,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.,Preliminary Examination of the Effects of Sodium Pyruvate Nasal Spray (N115) on Symptoms Associated With COVID19 Long Haulers.,"Active, not recruiting",NA,Phase 2/Phase 3,22,Actual,"Cellular Sciences, inc.",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:27:09Z,2021-12-02T04:27:09Z,90
NCT04732819,NA,2021-01-27,2021-07-22,NA,2021-09-01,2021-01-29,2021-02-01,Actual,2021-09-01,2021-09-05,Actual,NA,NA,NA,2021-09-01,2021-09-05,Actual,"December 21, 2020",Actual,2020-12-21,September 2021,2021-09-30,"April 16, 2021",Actual,2021-04-16,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,"The overall number of baseline participants includes the number of residents and staff in each arm. The unit analyzed was nursing home facility. Baseline characteristics were obtained for residents and nursing home facilities, but not for staff.",Improving COVID-19 Vaccine Uptake in Nursing Homes,IMPACT-C: Improving Vaccine Uptake in Skilled Nursing Facilities,Completed,NA,Not Applicable,23768,Actual,Brown University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The IPD and supporting documentation will be available through the CDCC within 6 months of the completion of the trial.,"Staff and patient data will be aggregated at the level of the facility. This data will be shared with the RADx-UP CDCC, who plans to make a central database that will ultimately be publicly available.",NA,Yes,"Data will be aggregated at the level of the facility. We will provide aggregated data to the RADx-UP Coordination and Data Collection Center (CDCC); however, given the nature of this data it will not be identifiable or linkable. The CDCC will facilitate cross-site pooling of data, whenever possible, and create a publicly available dataset with this information.",2021-12-02T06:21:40Z,2021-12-02T06:21:40Z,124
NCT04728802,NA,2021-01-27,2021-06-15,NA,2021-06-22,2021-01-27,2021-01-28,Actual,2021-06-15,2021-06-23,Actual,NA,NA,NA,2021-06-22,2021-06-24,Actual,"February 1, 2021",Actual,2021-02-01,June 2021,2021-06-30,"April 15, 2021",Actual,2021-04-15,"April 15, 2021",Actual,2021-04-15,NA,Interventional,NA,NA,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Completed,NA,Phase 3,645,Actual,"Applied Biology, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Available upon request after peer review and publication.,Available upon request at data@appliedbiology.com,NA,Yes,"Yes, study data sets will be made available upon request after peer review and publication.",2021-12-02T06:24:34Z,2021-12-02T06:24:34Z,195
NCT04728594,NA,2021-01-26,2021-07-16,NA,2021-07-22,2021-01-26,2021-01-28,Actual,2021-07-22,2021-07-26,Actual,NA,NA,NA,2021-07-22,2021-07-26,Actual,"January 15, 2021",Actual,2021-01-15,July 2021,2021-07-31,"January 20, 2021",Actual,2021-01-20,"January 17, 2021",Actual,2021-01-17,NA,Interventional,NA,"The baseline outcome measure was not applicable, since registration for vaccination was the outcome, and all participants were selected for not being registered.",Emails Promoting COVID-19 Vaccination Among Healthcare Workers,Evaluation of an Email Intervention Promoting COVID-19 Vaccination Among Healthcare Workers,Completed,NA,Not Applicable,9566,Actual,Geisinger Clinic,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will become available after publication of study results in a scientific journal and will be available as long as the Open Science Framework hosts the data.,The data on the Open Science Framework will be open to anyone requesting that information.,http://osf.io,Yes,Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency. This will include the essential data and code needed to replicate the analysis that yielded reported findings.,2021-12-02T06:24:45Z,2021-12-02T06:24:45Z,165
NCT04724538,NA,2020-12-29,2021-05-02,NA,2021-07-04,2021-01-23,2021-01-26,Actual,2021-07-04,2021-07-07,Actual,NA,NA,NA,2021-07-04,2021-07-07,Actual,"October 15, 2020",Actual,2020-10-15,July 2021,2021-07-31,"March 15, 2021",Actual,2021-03-15,"February 10, 2021",Actual,2021-02-10,NA,Interventional,NA,NA,Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19,Inhalation Low Dose Radionuclide Therapy in Comprehensive Treatment of COVID-19 Viral Pneumonia,Completed,NA,Phase 1/Phase 2,25,Actual,National Medical Research Radiological Centre of the Ministry of Health of Russia,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:28:21Z,2021-12-02T06:28:21Z,183
NCT04716426,NA,2021-01-18,2021-03-31,NA,2021-04-06,2021-01-18,2021-01-20,Actual,2021-04-06,2021-04-08,Actual,NA,NA,NA,2021-04-06,2021-04-08,Actual,"January 28, 2021",Actual,2021-01-28,April 2021,2021-04-30,"March 25, 2021",Actual,2021-03-25,"March 25, 2021",Actual,2021-03-25,NA,Interventional,NA,NA,APTâ„¢ T3X on the COVID-19 Contamination Rate,Use of APTâ„¢ T3X to Decrease the COVID-19 Contamination Rate in Humans,Completed,NA,Not Applicable,100,Actual,University of Nove de Julho,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:35:47Z,2021-12-02T06:35:47Z,272
NCT04698993,NA,2021-01-05,2021-06-16,NA,2021-07-19,2021-01-06,2021-01-07,Actual,2021-06-23,2021-06-25,Actual,NA,NA,NA,2021-07-19,2021-07-20,Actual,"February 12, 2021",Actual,2021-02-12,July 2021,2021-07-31,"March 22, 2021",Actual,2021-03-22,"March 22, 2021",Actual,2021-03-22,NA,Interventional,NA,NA,DrÃ¤ger COVID-19 Antigen Test Clinical Performance Study,DrÃ¤ger Antigen Test SARS-CoV-2 Clinical Performance Study,Terminated,NA,Not Applicable,388,Actual,DrÃ¤gerwerk AG & Co. KGaA,NA,2,NA,poor recruitment,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:50:47Z,2021-12-02T06:50:47Z,168
NCT04674644,NA,2020-12-16,2021-01-02,NA,2021-01-30,2020-12-17,2020-12-19,Actual,2021-01-27,2021-01-29,Actual,NA,NA,NA,2021-01-30,2021-02-02,Actual,"October 16, 2020",Actual,2020-10-16,January 2021,2021-01-31,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,NA,NA,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Suleyman Demirel University Faculty of Dentistry Pediatric Dentistry Department,Completed,NA,Not Applicable,850,Actual,Suleyman Demirel University,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:13:39Z,2021-12-02T07:13:39Z,338
NCT04673214,NA,2020-12-16,2021-03-08,NA,2021-08-12,2020-12-16,2020-12-17,Actual,2021-08-12,2021-08-16,Actual,NA,NA,NA,2021-08-12,2021-08-16,Actual,"December 16, 2020",Actual,2020-12-16,August 2021,2021-08-31,"February 25, 2021",Actual,2021-02-25,"February 25, 2021",Actual,2021-02-25,NA,Interventional,NA,"Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.",Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20,Completed,NA,Phase 3,114,Actual,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,SHARED VIA EMAIL IF OTHER RESEARCHERS REQUIRE IT,2021-12-02T07:15:11Z,2021-12-02T07:15:11Z,144
NCT04646109,NA,2020-11-15,2020-12-03,NA,2021-01-25,2020-11-25,2020-11-27,Actual,2021-01-25,2021-01-27,Actual,NA,NA,NA,2021-01-25,2021-01-27,Actual,"May 11, 2020",Actual,2020-05-11,January 2021,2021-01-31,"September 2, 2020",Actual,2020-09-02,"September 2, 2020",Actual,2020-09-02,NA,Interventional,NA,"36 patients were included in the study group. But, 6 patients in the study group were excluded from the study and analysis because ivermectin treatments were terminated due to the detection of a mutation that impairs ivermectin metabolism. As a result, overall number of baseline participants in the study group was 30.",Ivermectin for Severe COVID-19 Management,The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management,Completed,NA,Phase 3,66,Actual,Afyonkarahisar Health Sciences University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:38:08Z,2021-12-02T07:38:08Z,343
NCT04634903,NA,2020-11-11,2021-05-18,NA,2021-05-21,2020-11-17,2020-11-18,Actual,2021-05-21,2021-05-25,Actual,NA,NA,NA,2021-05-21,2021-05-25,Actual,"November 19, 2020",Actual,2020-11-19,May 2021,2021-05-31,"March 15, 2021",Actual,2021-03-15,"March 15, 2021",Actual,2021-03-15,NA,Interventional,NA,NA,"Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19",Comparing Two Online Single-Session Interventions for Adolescent Depression: Outcomes of a Randomized Trial,Completed,NA,Not Applicable,2452,Actual,Stony Brook University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Protocol and statistical plan have been posted to Open Science Framework prior to the start of this trial as part of study pre-registration (https://osf.io/kumdv/). Code will be made available upon publication of trial results.,NA,https://osf.io/8mk6x,Yes,NA,2021-12-02T07:47:37Z,2021-12-02T07:47:37Z,227
NCT04610489,NA,2020-10-27,2021-06-28,NA,2021-08-15,2020-10-29,2020-10-30,Actual,2021-08-15,2021-08-17,Actual,NA,NA,NA,2021-08-15,2021-08-17,Actual,"November 13, 2020",Actual,2020-11-13,August 2021,2021-08-31,"March 10, 2021",Actual,2021-03-10,"March 10, 2021",Actual,2021-03-10,NA,Interventional,NA,NA,Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19),Diagnostic Performance of an Antigen Test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Terminated,NA,Not Applicable,117,Actual,Carilion Clinic,NA,1,NA,Difficulty with recruiting for the study and with staffing the study.,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:11:03Z,2021-12-02T08:11:03Z,141
NCT04599959,NA,2020-10-22,2021-07-21,NA,2021-07-21,2020-10-22,2020-10-23,Actual,2021-07-21,2021-07-26,Actual,NA,NA,NA,2021-07-21,2021-07-26,Actual,"October 26, 2020",Actual,2020-10-26,July 2021,2021-07-31,"January 20, 2021",Actual,2021-01-20,"January 20, 2021",Actual,2021-01-20,NA,Interventional,NA,All eligible participants in this study who had been diagnosed with COVID-19 confirmed by polymerase chain reaction (PCR) test within the past 5 days before study entry.,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCR,"COVID-19 Tests: a Systematic Comparison of Viral RNA Test Sample Taking for RT-qPCR, in This Case With a Nasopharyngeal Swab or Saliva Collected With SalivetteÂ® Cortisol, to Diagnose SARS-CoV-2 Virus Infection",Completed,NA,Not Applicable,151,Actual,Boehringer Ingelheim,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:

studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).

For more details refer to: http://trials.boehringer-ingelheim.com/",2021-12-02T08:19:02Z,2021-12-02T08:19:02Z,166
NCT04596085,NA,2020-10-19,2021-07-29,NA,2021-08-11,2020-10-20,2020-10-22,Actual,2021-08-11,2021-08-12,Actual,NA,NA,NA,2021-08-11,2021-08-12,Actual,"September 16, 2020",Actual,2020-09-16,August 2021,2021-08-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,NA,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)","A Double Blind, Randomized, Placebo Controlled Study to Evaluate Efficacy and Safety of ""VIRACIDE"" in the Management of Corona Virus Disease 2019 (COVID-19)",Completed,NA,Not Applicable,118,Actual,"The Herb, Inc",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:22:23Z,2021-12-02T08:22:23Z,145
NCT04542694,NA,2020-09-04,2020-10-11,NA,2020-11-03,2020-09-04,2020-09-09,Actual,2020-11-03,2020-11-05,Actual,NA,NA,NA,2020-11-03,2020-11-05,Actual,"May 21, 2020",Actual,2020-05-21,November 2020,2020-11-30,"August 20, 2020",Actual,2020-08-20,"August 10, 2020",Actual,2020-08-10,NA,Interventional,NA,NA,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19",Completed,NA,Phase 3,200,Actual,"Promomed, LLC",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:03:26Z,2021-12-02T09:03:26Z,426
NCT04432272,NA,2020-06-12,2021-11-12,NA,2021-11-29,2020-06-12,2020-06-16,Actual,2021-11-12,2021-11-22,Actual,NA,NA,NA,2021-11-29,2021-12-01,Estimate,"July 16, 2020",Actual,2020-07-16,November 2021,2021-11-30,"November 28, 2020",Actual,2020-11-28,"November 13, 2020",Actual,2020-11-13,NA,Interventional,ABACCuS,NA,ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),Terminated,NA,Phase 2,54,Actual,William Beaumont Hospitals,NA,2,NA,"The EUA for CCP was updated by FDA, stipulating that only high titer units be used. This study required untitered units. The study became infeasible",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:34:55Z,2021-12-02T09:34:55Z,35
NCT05017493,NA,2021-04-04,2021-09-21,NA,2021-11-30,2021-08-16,2021-08-24,Actual,2021-11-30,2021-12-02,Estimate,NA,NA,NA,2021-11-30,2021-12-02,Estimate,"July 1, 2020",Actual,2020-07-01,November 2021,2021-11-30,"February 8, 2021",Actual,2021-02-08,"December 7, 2020",Actual,2020-12-07,NA,Interventional,NA,Both paitients who received and NOT received Xagrotin,"Treatment of Covid-19 With a Herbal Compound, Xagrotin","Treatment of Early-Stage Covid-19 With a Herbal Compound, Xagrotin",Completed,NA,Phase 1/Phase 2,661,Actual,Biomad AS,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-03T11:56:50Z,2021-12-03T11:56:50Z,34
NCT04317040,NA,2020-03-19,2021-09-28,NA,2021-10-13,2020-03-19,2020-03-20,Actual,2021-10-13,2021-10-15,Actual,NA,NA,NA,2021-10-13,2021-10-15,Actual,"April 24, 2020",Actual,2020-04-24,October 2021,2021-10-31,"October 20, 2020",Actual,2020-10-20,"October 20, 2020",Actual,2020-10-20,NA,Interventional,SAC-COVID,All randomized participants.,CD24Fc (MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007),"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Completed,NA,Phase 3,234,Actual,"OncoImmune, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-12-04T17:06:18Z,2021-12-04T17:06:18Z,82
NCT04374149,NA,2020-04-20,2021-11-19,NA,2021-11-30,2020-05-02,2020-05-05,Actual,2021-11-30,2021-12-02,Estimate,NA,NA,NA,2021-11-30,2021-12-02,Estimate,"April 30, 2020",Actual,2020-04-30,November 2021,2021-11-30,"December 1, 2020",Actual,2020-12-01,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,"Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)",Completed,NA,Phase 2,20,Actual,Prisma Health-Upstate,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Available April 2021 through December 2021,Data can be requested from the Principal Investigator via email and should include a description of the request and the associated project or use of the data.,NA,Yes,All individual participant date (IPD) that underlie results in a publication.,2021-12-03T12:03:23Z,2021-12-03T12:03:23Z,34
NCT04348500,NA,2020-04-13,2021-11-23,NA,2021-11-30,2020-04-13,2020-04-16,Actual,2021-11-30,2021-12-02,Estimate,NA,NA,NA,2021-11-30,2021-12-02,Estimate,"April 28, 2020",Actual,2020-04-28,November 2021,2021-11-30,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,Enrolled patients who received the initial dose of the IP were analyzed.,Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19),A Phase II Trial to Evaluate the Safety and Tolerability of ClazakizumabÂ® (Anti-IL-6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection,Completed,NA,Phase 2,17,Actual,Cedars-Sinai Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-03T12:03:33Z,2021-12-03T12:03:33Z,34
NCT04347941,NA,2020-04-08,2021-11-20,NA,2021-11-30,2020-04-14,2020-04-15,Actual,2021-11-30,2021-12-02,Estimate,NA,NA,NA,2021-11-30,2021-12-02,Estimate,"July 11, 2020",Actual,2020-07-11,November 2021,2021-11-30,"January 26, 2021",Actual,2021-01-26,"January 26, 2021",Actual,2021-01-26,NA,Interventional,APPROVE-CARE,Patients with suspected or confirmed COVID-19 pneumonia requiring high flow nasal cannula oxygen were randomized to either awake prone positioning or standard of care. The primary outcome was the requirement for invasive mechanical or death post 28 days randomization.,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Terminated,NA,Not Applicable,24,Actual,University College Hospital Galway,NA,2,NA,"Enrollment for trial was terminated on January 26, 2021 after a third interim analysis demonstrated that a pre-defined statistical criteria for efficacy were met as part of meta-trial study of awake prone positioning.",FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,up to 15 years post study,NA,NA,Yes,"Electronic Case report form following informed consent, all patient identification removed, and individual patient response to intervention will be shared.",2021-12-03T12:03:35Z,2021-12-03T12:03:35Z,34
NCT04331899,NA,2020-03-27,2021-04-08,NA,2021-11-24,2020-04-01,2020-04-02,Actual,2021-04-19,2021-04-22,Actual,NA,NA,NA,2021-11-24,2021-11-30,Estimate,"April 25, 2020",Actual,2020-04-25,November 2021,2021-11-30,"May 6, 2021",Actual,2021-05-06,"August 14, 2020",Actual,2020-08-14,NA,Interventional,COVID-Lambda,NA,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19",Completed,NA,Phase 2,120,Actual,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,The datasets generated and analyzed during the current study are permanently available in the Stanford Digital Repository,Full access,https://purl.stanford.edu/hc972ys6733,Yes,Sharing of generated and analyzed datasets.,2021-12-04T17:06:27Z,2021-12-04T17:06:27Z,40
NCT04347954,NA,2020-04-13,2021-10-15,NA,2021-10-19,2020-04-13,2020-04-15,Actual,2021-10-19,2021-10-21,Actual,NA,NA,NA,2021-10-19,2021-10-21,Actual,"August 15, 2020",Actual,2020-08-15,October 2021,2021-10-31,"December 13, 2020",Actual,2020-12-13,"December 13, 2020",Actual,2020-12-13,NA,Interventional,NA,Participants who received the allocated intervention and completed the study; participants with negative PCR nasal swab results at baseline or incomplete data were excluded.,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers,Completed,NA,Phase 1/Phase 2,47,Actual,Stanford University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:32Z,2021-12-04T17:06:32Z,76
NCT04349098,NA,2020-04-14,2021-10-05,NA,2021-10-27,2020-04-14,2020-04-16,Actual,2021-10-27,2021-11-01,Actual,NA,NA,NA,2021-10-27,2021-11-01,Actual,"April 17, 2020",Actual,2020-04-17,October 2021,2021-10-31,"October 5, 2020",Actual,2020-10-05,"October 5, 2020",Actual,2020-10-05,NA,Interventional,Coronavirus,PV 1-6 population included participants randomized into the study under protocol versions 1-6.,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection,Completed,NA,Phase 2,190,Actual,Karyopharm Therapeutics Inc,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-04T17:06:33Z,2021-12-04T17:06:33Z,68
NCT04353037,NA,2020-04-09,2021-07-22,NA,2021-10-15,2020-04-15,2020-04-20,Actual,2021-10-15,2021-10-19,Actual,NA,NA,NA,2021-10-15,2021-10-19,Actual,"April 7, 2020",Actual,2020-04-07,October 2021,2021-10-31,"July 11, 2020",Actual,2020-07-11,"July 11, 2020",Actual,2020-07-11,NA,Interventional,NA,All eligible randomized patients,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19,Terminated,NA,Phase 2,39,Actual,UnitedHealth Group,NA,2,NA,As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,1 year,NA,NA,Yes,Data will be collected and managed by Optumcare and UnitedHealth Group Research & Development. Redacted/aggregate data will be shared with the University Of Penn using approved data sharing protocols.,2021-12-04T17:06:35Z,2021-12-04T17:06:35Z,80
NCT04355767,NA,2020-04-17,2021-10-13,NA,2021-10-15,2020-04-17,2020-04-21,Actual,2021-10-15,2021-10-19,Actual,NA,NA,NA,2021-10-15,2021-10-19,Actual,"August 11, 2020",Actual,2020-08-11,October 2021,2021-10-31,"March 29, 2021",Actual,2021-03-29,"March 29, 2021",Actual,2021-03-29,NA,Interventional,C3PO,NA,Convalescent Plasma in Outpatients With COVID-19,Clinical-trial of COVID-19 Convalescent Plasma in Outpatients,Completed,NA,Phase 3,511,Actual,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data will be available indefinitely.,"Data requests will be managed by National Heart, Lung, and Blood Institute (NHLBI).",https://biodatacatalyst.nhlbi.nih.gov/,Yes,The complete de-identified patient data set will be shared.,2021-12-04T17:06:38Z,2021-12-04T17:06:38Z,80
NCT04358068,NA,2020-04-20,2021-02-24,NA,2021-11-12,2020-04-20,2020-04-22,Actual,2021-03-24,2021-04-01,Actual,NA,NA,NA,2021-11-12,2021-11-16,Estimate,"May 13, 2020",Actual,2020-05-13,October 2021,2021-10-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,Participants who initiated study treatment,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,"A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19",Terminated,NA,Phase 2,20,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,Slow enrollment and lack of community enthusiasm,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"With whom?

Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.

For what types of analyses?

To achieve aims in the proposal approved by the AIDS Clinical Trials Group.

By what mechanism will data be made available?

Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://submit.mis.s-3.net/ Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",NA,Yes,"Individual participant data that underlie results in the publication, after deidentification.",2021-12-04T17:06:41Z,2021-12-04T17:06:41Z,52
NCT04382053,NA,2020-05-08,2021-11-15,NA,2021-11-25,2020-05-08,2020-05-11,Actual,2021-11-25,2021-11-30,Estimate,NA,NA,NA,2021-11-25,2021-11-30,Estimate,"May 27, 2020",Actual,2020-05-27,November 2021,2021-11-30,"December 24, 2020",Actual,2020-12-24,"December 10, 2020",Actual,2020-12-10,NA,Interventional,NA,NA,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function",Completed,NA,Phase 2,143,Actual,Novartis,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-12-04T17:06:49Z,2021-12-04T17:06:49Z,39
NCT04388826,NA,2020-05-13,2021-10-20,NA,2021-11-22,2020-05-13,2020-05-14,Actual,2021-11-22,2021-11-24,Estimate,NA,NA,NA,2021-11-22,2021-11-24,Estimate,"June 18, 2020",Actual,2020-06-18,November 2021,2021-11-30,"August 13, 2021",Actual,2021-08-13,"December 18, 2020",Actual,2020-12-18,NA,Interventional,NA,NA,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,"Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)",Completed,NA,Phase 2,39,Actual,Veru Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:50Z,2021-12-04T17:06:50Z,42
NCT04475588,NA,2020-07-16,2020-08-02,NA,2021-06-10,2020-07-16,2020-07-17,Actual,2021-05-17,2021-05-20,Actual,NA,NA,NA,2021-06-10,2021-06-14,Actual,"May 1, 2020",Actual,2020-05-01,June 2021,2021-06-30,"July 7, 2020",Actual,2020-07-07,"July 7, 2020",Actual,2020-07-07,NA,Interventional,NA,NA,Efficacy and Safety of Itolizumab in COVID-19 Complications,"A Multi-Centre, Open Label, Two Arm Randomized, Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications",Completed,NA,Phase 2,32,Actual,Biocon Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:27:41Z,2021-12-04T22:27:41Z,207
NCT04401293,NA,2020-05-20,2021-10-29,NA,2021-11-17,2020-05-21,2020-05-26,Actual,2021-11-17,2021-11-22,Estimate,NA,NA,NA,2021-11-17,2021-11-22,Estimate,"April 26, 2020",Actual,2020-04-26,November 2021,2021-11-30,"May 14, 2021",Actual,2021-05-14,"May 14, 2021",Actual,2021-05-14,NA,Interventional,NA,NA,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial),Completed,NA,Phase 3,257,Actual,Northwell Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:56Z,2021-12-04T17:06:56Z,47
NCT04411628,NA,2020-05-29,2021-11-01,NA,2021-11-10,2020-05-29,2020-06-02,Actual,2021-11-01,2021-11-09,Actual,NA,NA,NA,2021-11-10,2021-11-12,Estimate,"May 28, 2020",Actual,2020-05-28,November 2021,2021-11-30,"August 26, 2020",Actual,2020-08-26,"August 26, 2020",Actual,2020-08-26,NA,Interventional,NA,All randomized participants who received at least one dose of study drug.,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,"A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19",Completed,NA,Phase 1,26,Actual,Eli Lilly and Company,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:58Z,2021-12-04T17:06:58Z,54
NCT04418947,NA,2020-05-29,2021-10-25,NA,2021-10-26,2020-06-02,2020-06-05,Actual,2021-10-26,2021-10-28,Actual,NA,NA,NA,2021-10-26,2021-10-28,Actual,"June 15, 2020",Actual,2020-06-15,October 2021,2021-10-31,"July 17, 2020",Actual,2020-07-17,"July 17, 2020",Actual,2020-07-17,NA,Interventional,NA,NA,Project Resurgence Communication Trial,Comparison of the Effectiveness of Communication Strategies on the Return to In-Person Visits to a Medical Center After the Emergence of COVID-19: A Randomized Trial,Completed,NA,Not Applicable,11120,Actual,University of Pennsylvania,NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:59Z,2021-12-04T17:06:59Z,69
NCT04497948,NA,2020-06-16,2021-10-29,NA,2021-11-16,2020-07-31,2020-08-04,Actual,2021-10-29,2021-11-05,Actual,NA,NA,NA,2021-11-16,2021-11-17,Estimate,"September 21, 2020",Actual,2020-09-21,November 2021,2021-11-30,"November 18, 2020",Actual,2020-11-18,"November 18, 2020",Actual,2020-11-18,NA,Interventional,NA,NA,Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19,"An Open-label, Multiple-dose Study of Acalabrutinib, Co Administered With a Proton-pump Inhibitor, in Participants Hospitalized With COVID-19",Terminated,NA,Phase 1,9,Actual,Acerta Pharma BV,NA,1,NA,"Data from the CALAVI Phase II trials for Acalabrutinib in patients hospitalized with COVID-19 did not meet their primary efficacy endpoints.

Based on this higher management made the decision to prematurely terminate the D822FC00005 PK study.",FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-12-04T17:07:20Z,2021-12-04T17:07:20Z,48
NCT04501952,NA,2020-08-05,2021-11-04,NA,2021-11-04,2020-08-05,2020-08-06,Actual,2021-11-04,2021-11-16,Estimate,NA,NA,NA,2021-11-04,2021-11-16,Estimate,"September 18, 2020",Actual,2020-09-18,November 2021,2021-11-30,"May 6, 2021",Actual,2021-05-06,"May 6, 2021",Actual,2021-05-06,NA,Interventional,NA,Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study treatment.,Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734â„¢) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting,"A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734â„¢) Treatment of COVID-19 in an Outpatient Setting",Terminated,NA,Phase 3,584,Actual,Gilead Sciences,NA,2,NA,The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns.,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-12-04T17:07:23Z,2021-12-04T17:07:23Z,60
NCT04504032,NA,2020-08-05,2021-09-29,NA,2021-10-20,2020-08-05,2020-08-07,Actual,2021-10-20,2021-10-22,Actual,NA,NA,NA,2021-10-20,2021-10-22,Actual,"September 2, 2020",Actual,2020-09-02,October 2021,2021-10-31,"March 29, 2021",Actual,2021-03-29,"March 10, 2021",Actual,2021-03-10,NA,Interventional,NA,NA,A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19),"A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (XareltoÂ®) for High Risk People With Mild COVID-19",Terminated,NA,Phase 2,497,Actual,Bill & Melinda Gates Medical Research Institute,NA,2,NA,"Based on Data Monitoring Committee''s recommendation on 3 February 2021, the study was stopped on 4 February 2021 due to futility.",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-04T17:07:25Z,2021-12-04T17:07:25Z,75
NCT04507867,NA,2020-08-06,2021-09-22,NA,2021-10-13,2020-08-09,2020-08-11,Actual,2021-10-13,2021-10-15,Actual,NA,NA,NA,2021-10-13,2021-10-15,Actual,"September 7, 2020",Actual,2020-09-07,October 2021,2021-10-31,"April 10, 2021",Actual,2021-04-10,"April 10, 2021",Actual,2021-04-10,NA,Interventional,NA,"all participants enrolled in the study, a total of 80 patients were compared.",Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Effect of a Nutritional Support System to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Completed,NA,Not Applicable,80,Actual,Anahuac University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:07:28Z,2021-12-04T17:07:28Z,82
NCT04701658,NA,2021-01-07,2021-11-11,NA,2021-11-11,2021-01-07,2021-01-08,Actual,2021-11-11,2021-11-16,Estimate,NA,NA,NA,2021-11-11,2021-11-16,Estimate,"February 1, 2021",Actual,2021-02-01,November 2021,2021-11-30,"June 22, 2021",Actual,2021-06-22,"June 22, 2021",Actual,2021-06-22,NA,Interventional,BLAZE-5,All participants who received single dose of Bamlanivimab.,A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),"A Prospective Cohort Study to Evaluate the Real-world Effectiveness of Bamlanivimab in Participants With Mild-to-moderate COVID-19 at High Risk for Progressing to Severe Illness, With Matched Controls",Completed,NA,Phase 2,109,Actual,Eli Lilly and Company,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2021-12-04T17:07:54Z,2021-12-04T17:07:54Z,53
NCT04706416,NA,2020-12-31,2021-10-27,NA,2021-11-02,2021-01-11,2021-01-12,Actual,2021-11-02,2021-11-04,Actual,NA,NA,NA,2021-11-02,2021-11-04,Actual,"November 14, 2020",Actual,2020-11-14,November 2021,2021-11-30,"January 15, 2021",Actual,2021-01-15,"January 15, 2021",Actual,2021-01-15,NA,Interventional,NA,NA,N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),Completed,NA,Phase 1,150,Actual,Quantinosis.ai LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"We will publish based on summary data, but make individual participant data available upon request. There are no plans to publish individual participant data.",2021-12-04T17:07:56Z,2021-12-04T17:07:56Z,62
NCT04502056,NA,2020-08-02,2021-05-28,NA,2021-07-24,2020-08-04,2020-08-06,Actual,2021-07-24,2021-07-27,Actual,NA,NA,NA,2021-07-24,2021-07-27,Actual,"August 7, 2020",Actual,2020-08-07,July 2021,2021-07-31,"September 6, 2020",Actual,2020-09-06,"September 6, 2020",Actual,2020-09-06,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Completed,NA,Not Applicable,20460,Actual,"National Bureau of Economic Research, Inc.",NA,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:27:27Z,2021-12-04T22:27:27Z,163
NCT04491994,NA,2020-07-28,2020-07-31,NA,2020-08-18,2020-07-28,2020-07-30,Actual,2020-08-18,2020-08-21,Actual,NA,NA,NA,2020-08-18,2020-08-21,Actual,"April 10, 2020",Actual,2020-04-10,August 2020,2020-08-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,COVID-19,sample size calculation was done and 540 patients enrolled,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial,Completed,NA,Phase 3,540,Actual,UNICEF,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,any time when asked,by email,NA,Yes,data can be shared on demand in SPSS sheet,2021-12-04T22:27:34Z,2021-12-04T22:27:34Z,503
NCT04491240,NA,2020-07-27,2020-10-21,NA,2020-10-28,2020-07-27,2020-07-29,Actual,2020-10-28,2020-11-04,Actual,NA,NA,NA,2020-10-28,2020-11-04,Actual,"July 20, 2020",Actual,2020-07-20,October 2020,2020-10-31,"October 20, 2020",Actual,2020-10-20,"October 1, 2020",Actual,2020-10-01,NA,Interventional,COVID-19EXO,NA,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,The Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Two-Sided Pneumonia,Completed,NA,Phase 1/Phase 2,30,Actual,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:27:35Z,2021-12-04T22:27:35Z,432
NCT04420273,NA,2020-06-03,2021-10-25,NA,2021-11-19,2020-06-05,2020-06-09,Actual,2021-11-19,2021-11-23,Estimate,NA,NA,NA,2021-11-19,2021-11-23,Estimate,"July 2, 2020",Actual,2020-07-02,November 2021,2021-11-30,"March 1, 2021",Actual,2021-03-01,"March 1, 2021",Actual,2021-03-01,NA,Interventional,TMD,NA,Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,Targeted Melanoma Detection With Skin Self-examination: Leveraging the Mammogram Encounter,Completed,NA,Not Applicable,1000,Actual,Northwestern University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:07:01Z,2021-12-04T17:07:01Z,45
NCT04435184,NA,2020-06-16,2021-11-03,NA,2021-11-03,2020-06-16,2020-06-17,Actual,2021-11-03,2021-11-09,Actual,NA,NA,NA,2021-11-03,2021-11-09,Actual,"July 9, 2020",Actual,2020-07-09,November 2021,2021-11-30,"January 4, 2021",Actual,2021-01-04,"November 28, 2020",Actual,2020-11-28,NA,Interventional,CRITICAL,Baseline characteristics data was collected for the 42 participants who completed the study.,Crizanlizumab for Treating COVID-19 Vasculopathy,Crizanlizumab for Treating COVID-19 Vasculopathy,Completed,NA,Phase 2,54,Actual,Johns Hopkins University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:07:07Z,2021-12-04T17:07:07Z,61
NCT04484207,NA,2020-07-21,2021-10-12,NA,2021-10-26,2020-07-21,2020-07-23,Actual,2021-10-26,2021-10-28,Actual,NA,NA,NA,2021-10-26,2021-10-28,Actual,"July 6, 2020",Actual,2020-07-06,October 2021,2021-10-31,"October 26, 2020",Actual,2020-10-26,"October 20, 2020",Actual,2020-10-20,NA,Interventional,NA,NA,Addressing COVID-19 Mental Health Problems Among US Veterans,Addressing COVID-19 Mental Health Problems Among US Veterans,Completed,NA,Not Applicable,172,Actual,"Research Foundation for Mental Hygiene, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,two months,Co-Is,NA,Yes,"Data will be shared as needed with investigators, IRB etc. A plan will be determined in the short future",2021-12-04T17:07:13Z,2021-12-04T17:07:13Z,69
NCT04492475,NA,2020-07-28,2021-10-28,NA,2021-11-18,2020-07-28,2020-07-30,Actual,2021-11-18,2021-11-22,Estimate,NA,NA,NA,2021-11-18,2021-11-22,Estimate,"August 5, 2020",Actual,2020-08-05,November 2020,2020-11-30,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)",Completed,NA,Phase 3,969,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T17:07:17Z,2021-12-04T17:07:17Z,46
NCT04523831,NA,2020-08-19,2020-09-30,NA,2020-10-07,2020-08-20,2020-08-24,Actual,2020-10-07,2020-10-09,Actual,NA,NA,NA,2020-10-07,2020-10-09,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"September 10, 2020",Actual,2020-09-10,"August 22, 2020",Actual,2020-08-22,NA,Interventional,NA,We followed intention to treat analysis; SPSS (Statistical Package for Social Sciences) version 20 was used to analyze data. To compare mean of the two group chi square test was done.,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care,Completed,NA,Phase 3,400,Actual,Dhaka Medical College,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,September 2020 to December 2020,Person who are investigating covid-19 in various aspects,NA,Yes,"Patients age, sex, Date of covid positive report, Symtoms,Date of covid negative report, post covid symptoms, time to recover.",2021-12-04T22:27:19Z,2021-12-04T22:27:19Z,453
NCT04463004,NA,2020-07-07,2021-08-04,NA,2021-08-04,2020-07-07,2020-07-09,Actual,2021-08-04,2021-08-11,Actual,NA,NA,NA,2021-08-04,2021-08-11,Actual,"September 2, 2020",Actual,2020-09-02,August 2021,2021-08-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,NA,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,NA,Phase 2,2,Actual,Virginia Commonwealth University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:27:48Z,2021-12-04T22:27:48Z,152
NCT04452435,NA,2020-06-29,2021-03-24,NA,2021-06-21,2020-06-29,2020-06-30,Actual,2021-04-28,2021-04-30,Actual,NA,NA,NA,2021-06-21,2021-06-23,Actual,"July 21, 2020",Actual,2020-07-21,June 2021,2021-06-30,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Interventional,NA,NA,Safety and Efficacy of C21 in Subjects With COVID-19,"A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation",Completed,NA,Phase 2,206,Actual,Vicore Pharma AB,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:27:54Z,2021-12-04T22:27:54Z,196
NCT04411667,NA,2020-05-29,2021-06-10,NA,2021-06-23,2020-06-01,2020-06-02,Actual,2021-06-23,2021-06-25,Actual,NA,NA,NA,2021-06-23,2021-06-25,Actual,"April 28, 2020",Actual,2020-04-28,June 2021,2021-06-30,"June 23, 2020",Actual,2020-06-23,"June 23, 2020",Actual,2020-06-23,NA,Interventional,NA,NA,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection,Completed,NA,Phase 4,34,Actual,Sharp HealthCare,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:13Z,2021-12-04T22:28:13Z,194
NCT04435808,NA,2020-06-04,2020-08-10,NA,2020-11-12,2020-06-16,2020-06-17,Actual,2020-11-12,2020-11-16,Actual,NA,NA,NA,2020-11-12,2020-11-16,Actual,"April 14, 2020",Actual,2020-04-14,November 2020,2020-11-30,"July 15, 2020",Actual,2020-07-15,"July 15, 2020",Actual,2020-07-15,NA,Interventional,NA,DSMB stopped the study,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Off Label Study to Evaluate the Efficacy of Hydroxychloroquine as Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers at High Risk of Occupational Exposure to SARS-CoV-2,Terminated,NA,Phase 1/Phase 2,1,Actual,University of New Mexico,NA,2,NA,Stopped for futility by DSMB,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:03Z,2021-12-04T22:28:03Z,417
NCT04409886,NA,2020-05-27,2021-05-25,NA,2021-06-25,2020-05-28,2020-06-01,Actual,2021-06-25,2021-06-29,Actual,NA,NA,NA,2021-06-25,2021-06-29,Actual,"June 1, 2020",Actual,2020-06-01,June 2021,2021-06-30,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,NA,Interventional,HBOT,NA,Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients,The Application of Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients - Randomized Controlled Trial,Terminated,NA,Phase 4,1,Actual,Maimonides Medical Center,NA,1,NA,"This study is part of a larger national study. Only 1 patient was enrolled at Maimonides; Medical Center. The study was ended by the sponsor because the PI left; funding ended; , and no time, or personnel to do the study",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data will not be shared,2021-12-04T22:28:13Z,2021-12-04T22:28:13Z,192
NCT04407507,NA,2020-05-27,2021-05-10,NA,2021-05-19,2020-05-27,2020-05-29,Actual,2021-05-19,2021-05-21,Actual,NA,NA,NA,2021-05-19,2021-05-21,Actual,"July 1, 2020",Actual,2020-07-01,May 2021,2021-05-31,"January 29, 2021",Actual,2021-01-29,"January 29, 2021",Actual,2021-01-29,NA,Interventional,SILVERBULLET,NA,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms","Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms",Completed,NA,Phase 2,66,Actual,Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:14Z,2021-12-04T22:28:14Z,229
NCT04402970,NA,2020-05-20,2021-03-12,NA,2021-04-12,2020-05-22,2020-05-27,Actual,2021-04-12,2021-04-14,Actual,NA,NA,NA,2021-04-12,2021-04-14,Actual,"June 19, 2020",Actual,2020-06-19,April 2021,2021-04-30,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,DORNASESARS2,NA,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2,Completed,NA,Phase 3,30,Actual,University of Missouri-Columbia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:16Z,2021-12-04T22:28:16Z,266
NCT04399980,NA,2020-05-21,2021-05-06,NA,2021-05-11,2020-05-21,2020-05-22,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"May 20, 2020",Actual,2020-05-20,May 2021,2021-05-31,"April 23, 2021",Actual,2021-04-23,"April 23, 2021",Actual,2021-04-23,NA,Interventional,NA,NA,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,NA,Phase 2,40,Actual,The Cleveland Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:20Z,2021-12-04T22:28:20Z,237
NCT04410159,NA,2020-05-27,2020-07-08,NA,2020-07-17,2020-05-28,2020-06-01,Actual,2020-07-17,2020-07-21,Actual,NA,NA,NA,2020-07-17,2020-07-21,Actual,"June 22, 2020",Actual,2020-06-22,July 2020,2020-07-31,"July 6, 2020",Actual,2020-07-06,"June 29, 2020",Actual,2020-06-29,NA,Interventional,GARGLES,NA,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,"A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients",Completed,NA,Phase 2,20,Actual,Universiti Sains Islam Malaysia,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,September to December 2020,email to drnurul@usim.edu.my,NA,Yes,The participant data from the final research dataset used in the published manuscript will be shared upon reasonable request. The protocol and data analysis will be shared in clinicaltrial,2021-12-04T22:28:08Z,2021-12-04T22:28:08Z,535
NCT04422561,NA,2020-06-06,2020-08-23,NA,2020-08-23,2020-06-06,2020-06-09,Actual,2020-08-23,2020-08-27,Actual,NA,NA,NA,2020-08-23,2020-08-27,Actual,"May 31, 2020",Actual,2020-05-31,August 2020,2020-08-31,"July 27, 2020",Actual,2020-07-27,"July 14, 2020",Actual,2020-07-14,NA,Interventional,NA,NA,Prophylactic Ivermectin in COVID-19 Contacts,Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19,Completed,NA,Phase 2/Phase 3,340,Actual,Zagazig University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:10Z,2021-12-04T22:28:10Z,498
NCT04421404,NA,2020-06-03,2021-05-18,NA,2021-08-23,2020-06-05,2020-06-09,Actual,2021-08-23,2021-08-25,Actual,NA,NA,NA,2021-08-23,2021-08-25,Actual,"June 9, 2020",Actual,2020-06-09,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,CAPRI,NA,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,A Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized Patients,Completed,NA,Phase 2,34,Actual,"University of California, San Francisco",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:11Z,2021-12-04T22:28:11Z,133
NCT04392219,NA,2020-04-29,2021-06-15,NA,2021-07-15,2020-05-15,2020-05-18,Actual,2021-07-15,2021-07-19,Actual,NA,NA,NA,2021-07-15,2021-07-19,Actual,"April 10, 2020",Actual,2020-04-10,July 2021,2021-07-31,"August 11, 2020",Actual,2020-08-11,"August 11, 2020",Actual,2020-08-11,NA,Interventional,NA,Safety population,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers",Completed,NA,Phase 1,130,Actual,"Ridgeback Biotherapeutics, LP",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:25Z,2021-12-04T22:28:25Z,172
NCT04392141,NA,2020-05-15,2020-11-25,NA,2021-04-16,2020-05-15,2020-05-18,Actual,2021-04-16,2021-04-20,Actual,NA,NA,NA,2021-04-16,2021-04-20,Actual,"April 1, 2020",Actual,2020-04-01,April 2021,2021-04-30,"November 1, 2020",Actual,2020-11-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,NA,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Application of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19,Completed,NA,Phase 1/Phase 2,120,Actual,Kermanshah University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:25Z,2021-12-04T22:28:25Z,262
NCT04401202,NA,2020-05-21,2021-05-23,NA,2021-05-25,2020-05-22,2020-05-26,Actual,2021-05-25,2021-05-26,Actual,NA,NA,NA,2021-05-25,2021-05-26,Actual,"May 21, 2020",Actual,2020-05-21,May 2021,2021-05-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,Nigella Sativa in COVID-19,"Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study",Completed,NA,Phase 2,183,Actual,King Abdulaziz University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-04T22:28:17Z,2021-12-04T22:28:17Z,223
NCT04372186,NA,2020-04-29,2021-08-04,NA,2021-09-23,2020-04-29,2020-05-01,Actual,2021-09-23,2021-09-27,Actual,NA,NA,NA,2021-09-23,2021-09-27,Actual,"May 14, 2020",Actual,2020-05-14,September 2021,2021-09-30,"December 1, 2021",Anticipated,2021-12-01,"August 18, 2020",Actual,2020-08-18,NA,Interventional,EMPACTA,"mITT population = all randomized participants who received study treatment, grouped according to the treatment assigned at randomization. Participants not receiving study treatment were excluded from analyses.",A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia","Active, not recruiting",NA,Phase 3,377,Actual,"Genentech, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-12-04T22:28:33Z,2021-12-04T22:28:33Z,102
NCT04371419,NA,2020-04-28,2021-05-28,NA,2021-07-24,2020-04-28,2020-05-01,Actual,2021-07-24,2021-07-27,Actual,NA,NA,NA,2021-07-24,2021-07-27,Actual,"May 13, 2020",Actual,2020-05-13,July 2021,2021-07-31,"May 26, 2020",Actual,2020-05-26,"May 24, 2020",Actual,2020-05-24,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,COVID-19 Health Messaging to Underserved Communities,COVID-19 Health Messaging to Underserved Communities,Completed,NA,Not Applicable,14267,Actual,"National Bureau of Economic Research, Inc.",NA,17,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Generally, social scientists post code and de-identified data when the findings are published","To be determined, if published alongside the paper data and code may be gated.",NA,Yes,"Generally, economists will post code and de-identified data when the findings are published",2021-12-04T22:28:34Z,2021-12-04T22:28:34Z,163
NCT04370834,NA,2020-04-30,2021-05-28,NA,2021-07-16,2020-04-30,2020-05-01,Actual,2021-05-28,2021-06-04,Actual,NA,NA,NA,2021-07-16,2021-07-20,Actual,"May 28, 2020",Actual,2020-05-28,July 2021,2021-07-31,"January 14, 2021",Actual,2021-01-14,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,NA,Tocilizumab for Patients With Cancer and COVID-19 Disease,Tocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19),Terminated,NA,Phase 2,1,Actual,National Cancer Institute (NCI),NA,1,NA,Other - Randomized data no longer support continuation,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://grants.nih.gov/policy/sharing.htm,Yes,"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.",2021-12-04T22:28:35Z,2021-12-04T22:28:35Z,171
NCT04390022,NA,2020-05-07,2020-12-09,NA,2020-12-10,2020-05-14,2020-05-15,Actual,2020-12-10,2020-12-17,Actual,NA,NA,NA,2020-12-10,2020-12-17,Actual,"July 31, 2020",Actual,2020-07-31,December 2020,2020-12-31,"October 9, 2020",Actual,2020-10-09,"September 17, 2020",Actual,2020-09-17,NA,Interventional,SAINT,NA,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission,Completed,NA,Phase 2,24,Actual,"Clinica Universidad de Navarra, Universidad de Navarra",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:26Z,2021-12-04T22:28:26Z,389
NCT04401579,NA,2020-05-22,2021-02-25,NA,2021-04-22,2020-05-22,2020-05-26,Actual,2021-04-22,2021-04-26,Actual,NA,NA,NA,2021-04-22,2021-04-26,Actual,"May 8, 2020",Actual,2020-05-08,April 2020,2020-04-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)",Completed,NA,Phase 3,1033,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:18Z,2021-12-04T22:28:18Z,256
NCT04365699,NA,2020-04-25,2021-09-01,NA,2021-09-10,2020-04-25,2020-04-28,Actual,2021-09-10,2021-09-16,Actual,NA,NA,NA,2021-09-10,2021-09-16,Actual,"April 8, 2020",Actual,2020-04-08,September 2021,2021-09-30,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,NA,Cardiovascular Effects of COVID-19,A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection,Completed,NA,Phase 2,81,Actual,NYU Langone Health,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Beginning 9 months and ending 36 months following article publication,Requests may be directed to Stuart.Katz@nyulangone.org.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to Stuart.Katz@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2021-12-04T22:28:38Z,2021-12-04T22:28:38Z,115
NCT04365153,NA,2020-04-24,2021-04-05,NA,2021-04-13,2020-04-24,2020-04-28,Actual,2021-04-13,2021-04-15,Actual,NA,NA,NA,2021-04-13,2021-04-15,Actual,"April 24, 2020",Actual,2020-04-24,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"February 2, 2021",Actual,2021-02-02,NA,Interventional,NA,NA,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation,Completed,NA,Phase 2,45,Actual,The Cleveland Clinic,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:38Z,2021-12-04T22:28:38Z,265
NCT04382066,NA,2020-05-07,2021-08-02,NA,2021-09-22,2020-05-08,2020-05-11,Actual,2021-09-22,2021-09-24,Actual,NA,NA,NA,2021-09-22,2021-09-24,Actual,"May 12, 2020",Actual,2020-05-12,September 2021,2021-09-30,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,APLICOV-PC,NA,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,"Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization",Completed,NA,Phase 1,46,Actual,PharmaMar,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Data of the final publication of the study will be shared upon request.,2021-12-04T22:28:30Z,2021-12-04T22:28:30Z,103
NCT04363736,NA,2020-04-21,2021-07-30,NA,2021-08-26,2020-04-24,2020-04-27,Actual,2021-08-26,2021-08-30,Actual,NA,NA,NA,2021-08-26,2021-08-30,Actual,"May 5, 2020",Actual,2020-05-05,August 2021,2021-08-31,"August 12, 2020",Actual,2020-08-12,"August 12, 2020",Actual,2020-08-12,NA,Interventional,MARIPOSA,NA,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,"A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia",Completed,NA,Phase 2,97,Actual,Hoffmann-La Roche,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-12-04T22:28:37Z,2021-12-04T22:28:37Z,130
NCT04380688,NA,2020-05-07,2021-08-19,NA,2021-09-08,2020-05-07,2020-05-08,Actual,2021-09-08,2021-09-13,Actual,NA,NA,NA,2021-09-08,2021-09-13,Actual,"June 13, 2020",Actual,2020-06-13,September 2021,2021-09-30,"November 16, 2020",Actual,2020-11-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,CALAVI US,NA,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,62,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",2021-12-04T22:28:31Z,2021-12-04T22:28:31Z,117
NCT04362813,NA,2020-04-24,2021-07-30,2021-02-08,2021-08-12,2020-04-24,2020-04-27,Actual,2021-08-12,2021-08-16,Actual,2021-08-12,2021-08-16,Actual,2021-08-12,2021-08-16,Actual,"April 30, 2020",Actual,2020-04-30,August 2021,2021-08-31,"December 22, 2020",Actual,2020-12-22,"September 16, 2020",Actual,2020-09-16,NA,Interventional,CAN-COVID,"While patient flow and baseline measure tables show 454 participants enrolled, only 451 randomized. 3 were ""mis-randomized"" i.e. assigned a randomization number in error and not treated.",Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,"Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)",Completed,NA,Phase 3,454,Actual,Novartis,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-12-04T22:28:40Z,2021-12-04T22:28:40Z,144
NCT04346199,NA,2020-04-09,2021-09-08,NA,2021-09-15,2020-04-14,2020-04-15,Actual,2021-09-08,2021-09-13,Actual,NA,NA,NA,2021-09-15,2021-09-17,Actual,"June 12, 2020",Actual,2020-06-12,September 2021,2021-09-30,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Interventional,CALAVI,NA,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,177,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.,2021-12-04T22:28:49Z,2021-12-04T22:28:49Z,110
NCT04356937,NA,2020-04-19,2021-06-23,NA,2021-07-23,2020-04-19,2020-04-22,Actual,2021-07-23,2021-07-27,Actual,NA,NA,NA,2021-07-23,2021-07-27,Actual,"April 20, 2020",Actual,2020-04-20,July 2021,2021-07-31,"August 27, 2020",Actual,2020-08-27,"July 13, 2020",Actual,2020-07-13,NA,Interventional,NA,All randomized patients,Efficacy of Tocilizumab on Patients With COVID-19,Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19,Completed,NA,Phase 3,243,Actual,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Request for IPD can be submitted to PI for review,2021-12-04T22:28:43Z,2021-12-04T22:28:43Z,164
NCT04362137,NA,2020-04-22,2021-04-15,NA,2021-10-07,2020-04-22,2020-04-24,Actual,2021-05-28,2021-06-02,Actual,NA,NA,NA,2021-10-07,2021-10-11,Actual,"May 2, 2020",Actual,2020-05-02,October 2021,2021-10-31,"October 17, 2020",Actual,2020-10-17,"October 17, 2020",Actual,2020-10-17,NA,Interventional,RUXCOVID,NA,Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,NA,Phase 3,432,Actual,Novartis,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-12-04T22:28:40Z,2021-12-04T22:28:40Z,88
NCT04354870,NA,2020-04-16,2021-09-29,NA,2021-10-04,2020-04-16,2020-04-21,Actual,2021-10-04,2021-10-06,Actual,NA,NA,NA,2021-10-04,2021-10-06,Actual,"April 3, 2020",Actual,2020-04-03,October 2021,2021-10-31,"October 1, 2020",Actual,2020-10-01,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,NA,COVID-19 PrEP HCW HCQ Study,Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2,Completed,NA,Phase 2,130,Actual,NYU Langone Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Study internal to NYU at this time,2021-12-04T22:28:44Z,2021-12-04T22:28:44Z,91
NCT04345653,NA,2020-04-08,2021-04-01,NA,2021-05-10,2020-04-13,2020-04-14,Actual,2021-05-05,2021-05-10,Actual,NA,NA,NA,2021-05-10,2021-05-12,Actual,"April 14, 2020",Actual,2020-04-14,May 2021,2021-05-31,"May 10, 2021",Actual,2021-05-10,"June 5, 2020",Actual,2020-06-05,NA,Interventional,NA,High risk healthcare providers,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers",Completed,NA,Phase 2,48,Actual,Hackensack Meridian Health,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:49Z,2021-12-04T22:28:49Z,238
NCT04343261,NA,2020-04-08,2020-09-01,NA,2020-09-22,2020-04-08,2020-04-13,Actual,2020-09-15,2020-09-17,Actual,NA,NA,NA,2020-09-22,2020-09-24,Actual,"April 10, 2020",Actual,2020-04-10,September 2020,2020-09-30,"August 13, 2020",Actual,2020-08-13,"July 23, 2020",Actual,2020-07-23,NA,Interventional,NA,NA,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Completed,NA,Phase 2,48,Actual,Saint Francis Care,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:50Z,2021-12-04T22:28:50Z,468
NCT04358081,NA,2020-04-08,2021-03-08,NA,2021-10-07,2020-04-20,2020-04-22,Actual,2021-03-08,2021-03-17,Actual,NA,NA,NA,2021-10-07,2021-10-11,Actual,"May 1, 2020",Actual,2020-05-01,October 2021,2021-10-31,"July 27, 2020",Actual,2020-07-27,"July 27, 2020",Actual,2020-07-27,NA,Interventional,NA,Full Analysis Set (FAS) was comprised of all participants to whom study treatment had been assigned by randomization excluding one mis-randomized participant.,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,"A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",Completed,NA,Phase 3,20,Actual,Novartis,NA,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-12-04T22:28:42Z,2021-12-04T22:28:42Z,88
NCT04343092,NA,2020-04-05,2020-06-11,NA,2020-11-02,2020-04-08,2020-04-13,Actual,2020-11-02,2020-11-04,Actual,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 18, 2020",Actual,2020-04-18,November 2020,2020-11-30,"June 1, 2020",Actual,2020-06-01,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,NA,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial),Completed,NA,Phase 1,16,Actual,University of Baghdad,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:51Z,2021-12-04T22:28:51Z,427
NCT04342663,NA,2020-04-08,2021-07-01,NA,2021-07-07,2020-04-08,2020-04-13,Actual,2021-07-07,2021-07-09,Actual,NA,NA,NA,2021-07-07,2021-07-09,Actual,"April 10, 2020",Actual,2020-04-10,July 2021,2021-07-31,"December 12, 2020",Actual,2020-12-12,"August 20, 2020",Actual,2020-08-20,NA,Interventional,STOP COVID,NA,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,NA,Phase 2,152,Actual,Washington University School of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:51Z,2021-12-04T22:28:51Z,180
NCT04342897,NA,2020-04-10,2021-08-04,NA,2021-08-04,2020-04-10,2020-04-13,Actual,2021-08-04,2021-08-12,Actual,NA,NA,NA,2021-08-04,2021-08-12,Actual,"April 20, 2020",Actual,2020-04-20,August 2021,2021-08-31,"October 12, 2020",Actual,2020-10-12,"October 12, 2020",Actual,2020-10-12,NA,Interventional,NA,All randomized participants who received at least 1 dose of study drug.,A Study of LY3127804 in Participants With COVID-19,"A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19",Terminated,NA,Phase 2,95,Actual,Eli Lilly and Company,NA,2,NA,Trial terminated for futility.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement,2021-12-04T22:28:51Z,2021-12-04T22:28:51Z,152
NCT04340557,NA,2020-04-06,2021-05-20,NA,2021-05-24,2020-04-08,2020-04-09,Actual,2021-05-24,2021-05-26,Actual,NA,NA,NA,2021-05-24,2021-05-26,Actual,"March 27, 2020",Actual,2020-03-27,May 2021,2021-05-31,"June 13, 2020",Actual,2020-06-13,"June 13, 2020",Actual,2020-06-13,NA,Interventional,NA,NA,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection,Completed,NA,Phase 4,31,Actual,Sharp HealthCare,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:52Z,2021-12-04T22:28:52Z,224
NCT04333225,NA,2020-04-01,2021-08-02,NA,2021-08-18,2020-04-02,2020-04-03,Actual,2021-08-18,2021-08-20,Actual,NA,NA,NA,2021-08-18,2021-08-20,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures,Completed,NA,Phase 2,221,Actual,Baylor Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:58Z,2021-12-04T22:28:58Z,138
NCT04332991,NA,2020-03-31,2021-02-09,NA,2021-03-12,2020-03-31,2020-04-03,Actual,2021-03-12,2021-03-17,Actual,NA,NA,NA,2021-03-12,2021-03-17,Actual,"April 2, 2020",Actual,2020-04-02,March 2021,2021-03-31,"July 23, 2020",Actual,2020-07-23,"June 19, 2020",Actual,2020-06-19,NA,Interventional,ORCHID,NA,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,NA,Phase 3,479,Actual,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:58Z,2021-12-04T22:28:58Z,297
NCT04338009,NA,2020-04-01,2021-01-28,NA,2021-04-07,2020-04-07,2020-04-08,Actual,2021-04-07,2021-04-09,Actual,NA,NA,NA,2021-04-07,2021-04-09,Actual,"March 31, 2020",Actual,2020-03-31,April 2021,2021-04-30,"August 20, 2020",Actual,2020-08-20,"August 20, 2020",Actual,2020-08-20,NA,Interventional,REPLACECOVID,NA,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019,Completed,NA,Not Applicable,152,Actual,University of Pennsylvania,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Not making it available,2021-12-04T22:28:54Z,2021-12-04T22:28:54Z,271
NCT04338074,NA,2020-04-06,2021-04-21,NA,2021-05-11,2020-04-06,2020-04-08,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"June 1, 2020",Actual,2020-06-01,May 2021,2021-05-31,"April 21, 2021",Actual,2021-04-21,"April 21, 2021",Actual,2021-04-21,NA,Interventional,TCOutpatient,NA,TXA and Corona Virus 2019 (COVID19) in Outpatients,Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients,Terminated,NA,Phase 2,5,Actual,University of Alabama at Birmingham,NA,2,NA,Lack of recruitment,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:54Z,2021-12-04T22:28:54Z,237
NCT04329923,NA,2020-03-30,2020-11-13,NA,2020-12-08,2020-03-30,2020-04-01,Actual,2020-12-08,2020-12-10,Actual,NA,NA,NA,2020-12-08,2020-12-10,Actual,"April 9, 2020",Actual,2020-04-09,December 2020,2020-12-31,"November 13, 2020",Actual,2020-11-13,"November 11, 2020",Actual,2020-11-11,NA,Interventional,PATCH,All randomized patients,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,NA,Phase 2,173,Actual,University of Pennsylvania,NA,6,NA,Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met pre-specificied futility analysis at planned second interim analysis,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,One year after study completion,Open access,NA,Yes,We will publish our results in a peer-reviewed journal and make available de-identified data for additional analysis,2021-12-04T22:29:04Z,2021-12-04T22:29:04Z,391
NCT04328467,NA,2020-03-27,2021-06-25,NA,2021-06-30,2020-03-30,2020-03-31,Actual,2021-06-25,2021-06-30,Actual,NA,NA,NA,2021-06-30,2021-07-02,Actual,"April 6, 2020",Actual,2020-04-06,June 2021,2021-06-30,"July 13, 2020",Actual,2020-07-13,"July 13, 2020",Actual,2020-07-13,NA,Interventional,NA,NA,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1483,Actual,University of Minnesota,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-04T22:29:05Z,2021-12-04T22:29:05Z,187
NCT04327388,NA,2020-03-26,2021-04-28,NA,2021-05-11,2020-03-26,2020-03-31,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 28, 2020",Actual,2020-03-28,May 2021,2021-05-31,"September 2, 2020",Actual,2020-09-02,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,Analysis was performed on randomized population.,Sarilumab COVID-19,"An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Completed,NA,Phase 3,420,Actual,Sanofi,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-12-04T22:29:05Z,2021-12-04T22:29:05Z,237
NCT04332081,NA,2020-03-30,2021-06-14,NA,2021-06-16,2020-04-01,2020-04-02,Actual,2021-06-16,2021-06-22,Actual,NA,NA,NA,2021-06-16,2021-06-22,Actual,"April 6, 2020",Actual,2020-04-06,June 2021,2021-06-30,"May 29, 2020",Actual,2020-05-29,"May 29, 2020",Actual,2020-05-29,NA,Interventional,NA,NA,Hyperbaric Oxygen for COVID-19 Patients,Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19,Terminated,NA,Not Applicable,80,Actual,NYU Langone Health,NA,2,NA,The IRB has determined that the design of this trial should be changed to a randomized controlled trial. A new record will be created for the redesigned study.,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,Immediately following publication. No end date.,"Requests should be directed to David.Lee@nyulangone.org and Scott.Gorenstein@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be made available immediately following publication, upon reasonable request by an investigator who proposes to use the data.",2021-12-04T22:29:01Z,2021-12-04T22:29:01Z,201
NCT04322682,NA,2020-03-23,2021-08-10,NA,2021-09-03,2020-03-25,2020-03-26,Actual,2021-09-03,2021-09-08,Actual,NA,NA,NA,2021-09-03,2021-09-08,Actual,"March 23, 2020",Actual,2020-03-23,September 2021,2021-09-30,"January 21, 2021",Actual,2021-01-21,"January 21, 2021",Actual,2021-01-21,NA,Interventional,COVID-19,Characteristics of the patients at randomisation in the intent-to-treat population.,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Terminated,NA,Phase 3,4506,Actual,Montreal Heart Institute,NA,2,NA,"Due to several considerations (logistical, human and budgetary), the study was stopped early.",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:29:07Z,2021-12-04T22:29:07Z,122
NCT04322396,NA,2020-03-23,2021-06-15,NA,2021-06-28,2020-03-24,2020-03-26,Actual,2021-06-24,2021-06-28,Actual,NA,NA,NA,2021-06-28,2021-06-29,Actual,"April 6, 2020",Actual,2020-04-06,June 2021,2021-06-30,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,ProPAC-COVID,NA,Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,"Proactive Protection With Azithromycin and Hydroxychloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19",Terminated,NA,Phase 2,117,Actual,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",NA,2,NA,Recommended by the DSMB,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:29:08Z,2021-12-04T22:29:08Z,189
NCT04335136,NA,2020-04-01,2021-06-07,NA,2021-07-29,2020-04-03,2020-04-06,Actual,2021-07-29,2021-08-02,Actual,NA,NA,NA,2021-07-29,2021-08-02,Actual,"April 30, 2020",Actual,2020-04-30,July 2021,2021-07-31,"December 26, 2020",Actual,2020-12-26,"December 26, 2020",Actual,2020-12-26,NA,Interventional,APN01-COVID-19,All randomized patients who received at least 1 dose of investigational medicinal product (IMP).,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Completed,NA,Phase 2,185,Actual,Apeiron Biologics,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:56Z,2021-12-04T22:28:56Z,158
NCT04335552,NA,2020-04-03,2021-05-03,NA,2021-05-13,2020-04-03,2020-04-06,Actual,2021-05-03,2021-05-12,Actual,NA,NA,NA,2021-05-13,2021-05-17,Actual,"April 17, 2020",Actual,2020-04-17,May 2021,2021-05-31,"June 26, 2020",Actual,2020-06-26,"June 17, 2020",Actual,2020-06-17,NA,Interventional,NA,NA,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",Terminated,NA,Phase 2,11,Actual,Duke University,NA,4,NA,"Poor recruitment, strong evidence from larger trials of no therapeutic benefit",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:56Z,2021-12-04T22:28:56Z,235
NCT04334876,NA,2020-04-02,2021-07-19,NA,2021-09-10,2020-04-02,2020-04-06,Actual,2021-09-10,2021-09-16,Actual,NA,NA,NA,2021-09-10,2021-09-16,Actual,"April 1, 2020",Actual,2020-04-01,September 2021,2021-09-30,"January 1, 2021",Actual,2021-01-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,COVID-Antibody,NA,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers and Candidacy for Convalescent Plasma Therapy/Prophylaxis,Completed,NA,Not Applicable,571,Actual,Indiana University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:57Z,2021-12-04T22:28:57Z,115
NCT04320615,NA,2020-03-23,2021-06-23,NA,2021-06-28,2020-03-23,2020-03-25,Actual,2021-06-28,2021-06-30,Actual,NA,NA,NA,2021-06-28,2021-06-30,Actual,"April 3, 2020",Actual,2020-04-03,June 2021,2021-06-30,"July 28, 2020",Actual,2020-07-28,"June 24, 2020",Actual,2020-06-24,NA,Interventional,COVACTA,NA,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,452,Actual,Hoffmann-La Roche,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform https://vivli.org.

Further details on Roche's criteria for eligible studies are available here: https://vivli.org.

For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm",2021-12-04T22:29:09Z,2021-12-04T22:29:09Z,189
NCT04332107,NA,2020-03-30,2021-08-09,NA,2021-10-05,2020-04-01,2020-04-02,Actual,2021-08-31,2021-09-09,Actual,NA,NA,NA,2021-10-05,2021-10-07,Actual,"May 22, 2020",Actual,2020-05-22,October 2021,2021-10-31,"March 30, 2021",Actual,2021-03-30,"March 16, 2021",Actual,2021-03-16,NA,Interventional,ACTION,A single participant in the Azithromycin group did not have baseline symptom information.,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19,Terminated,NA,Phase 3,263,Actual,"University of California, San Francisco",NA,2,NA,Futility,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-12-04T22:29:02Z,2021-12-04T22:29:02Z,90
NCT04292899,NA,2020-02-28,2020-12-15,NA,2020-12-15,2020-02-28,2020-03-03,Actual,2020-12-15,2020-12-31,Actual,NA,NA,NA,2020-12-15,2020-12-31,Actual,"March 6, 2020",Actual,2020-03-06,December 2020,2020-12-31,"June 30, 2020",Actual,2020-06-30,"April 9, 2020",Actual,2020-04-09,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment.

Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into part B of the study and received at least 1 dose of study treatment.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,Completed,NA,Phase 3,4891,Actual,Gilead Sciences,NA,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-12-04T22:29:24Z,2021-12-04T22:29:24Z,384
NCT04308668,NA,2020-03-11,2021-04-26,NA,2021-05-11,2020-03-11,2020-03-16,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 17, 2020",Actual,2020-03-17,May 2021,2021-05-31,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Interventional,COVID-19 PEP,NA,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1312,Actual,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,at time of publication,To be publicly provided. Please register at the website to receive the dataset.,https://covidpep.umn.edu/data,Yes,De-identified dataset will be available within 1 month of publication.,2021-12-04T22:29:18Z,2021-12-04T22:29:18Z,237
NCT04315298,NA,2020-03-15,2021-07-23,NA,2021-09-16,2020-03-17,2020-03-19,Actual,2021-09-16,2021-09-23,Actual,NA,NA,NA,2021-09-16,2021-09-23,Actual,"March 18, 2020",Actual,2020-03-18,September 2021,2021-09-30,"September 2, 2020",Actual,2020-09-02,"July 24, 2020",Actual,2020-07-24,NA,Interventional,NA,NA,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Completed,NA,Phase 2/Phase 3,1912,Actual,Regeneron Pharmaceuticals,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All IPD that underlie publicly available results will be considered for sharing,2021-12-04T22:29:12Z,2021-12-04T22:29:12Z,109
NCT04292730,NA,2020-02-28,2020-12-15,NA,2021-01-21,2020-02-28,2020-03-03,Actual,2021-01-21,2021-01-26,Actual,NA,NA,NA,2021-01-21,2021-01-26,Actual,"March 15, 2020",Actual,2020-03-15,January 2021,2021-01-31,"June 26, 2020",Actual,2020-06-26,"April 29, 2020",Actual,2020-04-29,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment or completed the Day 1 visit (SOC only group).

Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into Part B of the study and received at least 1 dose of study drug.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,Completed,NA,Phase 3,1113,Actual,Gilead Sciences,NA,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-12-04T22:29:25Z,2021-12-04T22:29:25Z,347
NCT04280705,NA,2020-02-20,2020-09-16,NA,2020-12-05,2020-02-20,2020-02-21,Actual,2020-09-22,2020-09-25,Actual,NA,NA,NA,2020-12-05,2020-12-09,Actual,"February 21, 2020",Actual,2020-02-21,April 2020,2020-04-30,"May 21, 2020",Actual,2020-05-21,"May 21, 2020",Actual,2020-05-21,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,1062,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:29:29Z,2021-12-04T22:29:29Z,394
